胰腺癌治疗的分子靶点：临床与实验研究
Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
作者信息
Matsuoka Tasuku, Yashiro Masakazu
机构信息
Tasuku Matsuoka, Masakazu Yashiro, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
出版信息
World J Gastroenterol. 2016 Jan 14;22(2):776-89. doi: 10.3748/wjg.v22.i2.776.
Abstract
Pancreatic cancer is the fourth most common cause of cancer deaths worldwide. Although recent therapeutic developments for patients with pancreatic cancer have provided survival benefits, the outcomes for patients with pancreatic cancer remain unsatisfactory. Molecularly targeted cancer therapy has advanced in the past decade with the use of a number of pathways as candidates of therapeutic targets. This review summarizes the molecular features of this refractory disease while focusing on the recent clinical and experimental findings on pancreatic cancer. It also discusses the data supporting current standard clinical outcomes, and offers conclusions that may improve the management of pancreatic cancer in the future.
摘要
胰腺癌是全球第四大常见癌症死因。尽管近期针对胰腺癌患者的治疗进展带来了生存获益，但胰腺癌患者的治疗结果仍不尽人意。在过去十年中，分子靶向癌症治疗取得了进展，多种信号通路被用作治疗靶点的候选对象。本综述总结了这种难治性疾病的分子特征，同时重点关注胰腺癌最近的临床和实验研究结果。它还讨论了支持当前标准临床疗效的数据，并得出可能改善未来胰腺癌治疗管理的结论。
相似文献
1
Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
World J Gastroenterol. 2016 Jan 14;22(2):776-89. doi: 10.3748/wjg.v22.i2.776.
2
Novel therapeutic targets for pancreatic cancer.
World J Gastroenterol. 2014 Aug 21;20(31):10825-44. doi: 10.3748/wjg.v20.i31.10825.
3
Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Cancer Lett. 2015 Jul 10;363(1):1-6. doi: 10.1016/j.canlet.2015.04.009. Epub 2015 Apr 15.
4
Targeting dynamics of subclones of GI, liver and pancreatic cancers.
Expert Rev Gastroenterol Hepatol. 2016 Jul;10(7):773-6. doi: 10.1080/17474124.2016.1179578. Epub 2016 May 3.
5
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.
6
Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
Oncology (Williston Park). 2017 Mar 15;31(3):159-66, 168.
7
Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
World J Gastroenterol. 2016 May 21;22(19):4638-50. doi: 10.3748/wjg.v22.i19.4638.
8
Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):893-905. doi: 10.1586/17474124.2016.1153424. Epub 2016 Feb 26.
9
New targeted therapies in pancreatic cancer.
World J Gastroenterol. 2015 May 28;21(20):6127-45. doi: 10.3748/wjg.v21.i20.6127.
10
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential.
Expert Rev Gastroenterol Hepatol. 2018 May;12(5):471-478. doi: 10.1080/17474124.2018.1463157. Epub 2018 Apr 18.
引用本文的文献
1
Recent Advances and Challenges in the Treatment of Advanced Pancreatic Cancer: An Update on Completed and Ongoing Clinical Trials.
Cancers (Basel). 2025 Apr 14;17(8):1319. doi: 10.3390/cancers17081319.
2
1,2,4-Triazole-Tethered Indolinones as New Cancer-Fighting Small Molecules Targeting VEGFR-2: Synthesis, Biological Evaluations and Molecular Docking.
Pharmaceuticals (Basel). 2024 Jan 8;17(1):81. doi: 10.3390/ph17010081.
3
The MyD88 inhibitor, ST2825, induces cell cycle arrest and apoptosis by suppressing the activation of the NF‑κB/AKT1/p21 pathway in pancreatic cancer.
Oncol Rep. 2023 Aug;50(2). doi: 10.3892/or.2023.8585. Epub 2023 Jun 16.
4
Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities.
Cancers (Basel). 2023 Apr 18;15(8):2354. doi: 10.3390/cancers15082354.
5
Integrating multidimensional data for clustering analysis with applications to cancer patient data.
J Am Stat Assoc. 2021;116(533):14-26. doi: 10.1080/01621459.2020.1730853. Epub 2020 Mar 19.
6
Bioinformatics-Based Analysis: Noncoding RNA-Mediated COL10A1 Is Associated with Poor Prognosis and Immune Cell Infiltration in Pancreatic Cancer.
J Healthc Eng. 2022 Sep 5;2022:7904982. doi: 10.1155/2022/7904982. eCollection 2022.
7
Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects.
Int J Mol Sci. 2022 Sep 4;23(17):10132. doi: 10.3390/ijms231710132.
8
Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival.
Oncotarget. 2022 Jun 15;13:828-841. doi: 10.18632/oncotarget.28242. eCollection 2022.
9
A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study.
BMC Gastroenterol. 2022 Jun 3;22(1):279. doi: 10.1186/s12876-022-02362-2.
10
Treatment optimization of locally advanced and metastatic pancreatic cancer (Review).
Int J Oncol. 2021 Dec;59(6). doi: 10.3892/ijo.2021.5290. Epub 2021 Dec 3.
本文引用的文献
1
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.
Mol Cancer Ther. 2015 Jul;14(7):1532-9. doi: 10.1158/1535-7163.MCT-15-0028. Epub 2015 Apr 30.
2
New insights into pancreatic cancer stem cells.
World J Stem Cells. 2015 Apr 26;7(3):547-55. doi: 10.4252/wjsc.v7.i3.547.
3
Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer.
Mol Cancer. 2015 Apr 25;14:94. doi: 10.1186/s12943-015-0358-5.
4
Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
Oncotarget. 2015 Jun 20;6(17):14940-52. doi: 10.18632/oncotarget.3613.
5
Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors.
BMC Cancer. 2015 Apr 4;15:223. doi: 10.1186/s12885-015-1249-2.
6
Cancer stem cells as therapeutic targets of hepato-biliary-pancreatic cancers.
J Hepatobiliary Pancreat Sci. 2015 Jul;22(7):531-7. doi: 10.1002/jhbp.248. Epub 2015 Apr 14.
7
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
Ann Oncol. 2015 Jun;26(6):1194-1200. doi: 10.1093/annonc/mdv133. Epub 2015 Apr 9.
8
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
Cancer Chemother Pharmacol. 2015 Jun;75(6):1135-41. doi: 10.1007/s00280-015-2730-y. Epub 2015 Mar 31.
9
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
Bioorg Med Chem. 2015 Apr 1;23(7):1386-94. doi: 10.1016/j.bmc.2015.02.053. Epub 2015 Mar 6.
10
Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.
Jpn J Clin Oncol. 2015 May;45(5):439-48. doi: 10.1093/jjco/hyv011. Epub 2015 Feb 3.
Zotero 插件